Aging Pharma Conference Program - Basel, September 23-24
International symposium on geroprotectors: Practical Applications of Aging Research for Drug Discovery (free registration) Aging lies at the core of every age-related disease and affects every person on the planet. It represents an unbearable toll on the economies of the developed countries resulting in over two trillion dollars in direct medical costs, costs of caring and lost productivity in the US and EU alone. Yet, pharmaceutical companies fail to see the practical applications of aging research as many early experiments with drugs that held promise in slowing the aging processes resulted in commercial failures and write offs. Lack of business models, regulation and absence of a clear set of aging biomarkers make it difficult for large pharmaceutical companies to fully engage in aging research. Unlike other events that are geared towards academia or have a broad range of topics, this forum intends to focus on drug discovery and pharmaceuticals that may have a role in postponing the aging processes, preventing the age-related diseases and evaluating the effectiveness of various small molecules with geroprotective properties. The event will showcase the research projects in aging research to the leaders of the pharmaceutical industry. The symposium will comprise into the three sessions relevant to the drug discovery companies. Each session will be chaired by the top expert in the field: Session I: Predicting the activity of geroprotective drugs: in-silico screening, omics data analysis and rational drug design Session II: Drugs with the potential geroprotective properties Session III: Aging Biomarkers: how do we measure aging and geroprotective efficacy? Session IV: Trends in Aging Research and Drug Discovery
Aging Pharma Conference Program - Basel, September 23-24
- 1. International Symposium on Geroprotectors: Practical applications of aging research for drug discovery 23.09, Tuesday: Keynotes/General 08.00 - 08.30 Advances in aging biomarkers and drugs with geroprotective properties Brian Kennedy Director, CEO Buck Institute for Aging Research USA 08.30 - 09.00 New approaches in aging diagnostics and interventions Charles Cantor Professor Boston University USA 09.00 - 9.30 TBD Nir Barzilai Director Albert Einstein College of Medicine USA 9.30-10.30 10.30 - 11.00 Novel methods for selecting targeted drugs for personalized medicine in oncology Anton Buzdin President, CEO Pathway Pharmaceuticals Hong Kong 11.00 - 11.30 Bioinformatic analysis of the omics data from long-lived animals for geroprotector discovery Joao Pedro De Magalhaes Lab Head University of Liverpool UK 11.30 - 12.00 In silico screening for novel drugs with geroprotective properties Alexander Zhavoronkov Director The Biogerontology Research Foundation UK Lunch 13.30-14.15 TBD Dr. J旦rg Reinhardt Chairman Novartis Global Session II: Drugs with the potential geroprotective properties Session Chair: TBD 14.30 - 15.00 Using novel isotopically-fortified organic compounds to slow down the aging processes and treat age-related diseases Robert Molinari CEO Retrotope, Inc USA 15.00 - 15.30 Advances in the Advanced Glycation Endproduct (AGE) breakers William Bains Head of the SENS Laboratory Cambridge UK 15.30 - 16.00 Overview of the possible geroprotectors Sven Bulterijs Post-grad researcher Yale University USA 16.00 - 16.30 Coffee Break 16.30 - 17.00 Applied Epigenetics of Aging and Longevity Olga Kovalchuk Professor, Lab Head University of Lethbridge Canada 24.09, Wednesday: Keynotes/General 08.00 - 08.30 Rapamycin and other geroprotectors Mikhail Blagosklonny Professor, editor-in- chief of Aging Rosewell Park, NY USA 08.30 - 09.00 TBD Blanka Rogina Director Genetics & Developmental Biology Graduate Program University of Connecticut USA 09.00 - 09.30 TBD James Kirkland Professor Mayo Clinic USA 09.30 - 10.00 How to Solve Genetic Disease on a Population Scale Barry Merriman Professor/ Lead System Architect, CSO UCLA/Thermo Fisher Scientific USA 10.00 - 10.30 Coffee Break 10.30 - 11.00 Lessons learned from the EU FP7 MARKAGE Project Alexander B端rkle Professor, MARK- AGE Co-ordinator University of Konstanz Germany 11.00-11.30 Comparative genomics of aging and longevity Vadim Gladyshev Professor, Department of Medicine, Harvard Medical School Director of Redox Medicine, Medicine, Brigham And Women's Hospital Harvard USA 11.00 - 11.30 Gene expression patterns in progeria and age-related diseases Antonei Benjamin Csoka Assoc. Professor Howard University USA 11.30 - 12.00 Genetic and Epigenetic Biomarkers of Aging Alexey A Moskalev Professor, head of the laboratory Moscow Institute of Physics and Technology Russia Lunch 13.30-14.15 TBD Prof. Patrick Aebischer President Ecole Polytechnique F辿d辿rale de Lausanne (EPFL) SW Session IV: Trends in Aging Research for Drug Discovery Session Chair: Richard Faragher, PhD 14.30 - 15.00 Ageing Research and Regenerative Medicine Industry Outlook Charles Groome and Geoffrey Furlonger Head of Communications Aging Analytics UK 15.00 - 15.30 Industry Partnerships for Ageing Research David Brindley Research Fellow in Cell Therapy Commercialization / Researcher Harvard Stem Cell Institute / University of Oxford, NDORMS UK 15.30 - 16.00 Big Data in Biomedicine: Applying machine learning to predict the outcomes of biomedical research projects Dmitry Kaminskiy Director, Senior Partner Deep Knowledge Ventures Hong Kong 16.00 - 16.30 Coffee Break 16.30 - 17.00 TBD Richard Faragher Professor University of Brighton UK Backup keynote speaker (23 or 24) TBD New drug discovery: AK-1 for radioprotection, AK-2 for antiviral and AK-3 for anti-aging Grace Wong CEO Actokine USA ROUND TABLE (Bhupinder Bullar to organize): how can large pharma engage in aging research? Session I: Predicting the activity of geroprotective drugs: in-silico screening, omics data analysis and rational drug design; Session Chair: Joao Pedro Megalhaes, PhD Session III: Aging Biomarkers: how do we measure aging and geroprotective efficacy Session Chair: Alexander B端rkle, PhD